Radcliffe Cardiology’s Post

Happy #FDAFriday! A "Teaching Resource Guide" was released by the FDA as a toolkit to educate health care professionals about biologics, mainly focusing on biosimilars and interchangeable biosimilars. *Sarfaraz K. Niazi, PhD, provides clarity on the: - goals and objectives - 2 levels of learning - types of resources - additional FDA resources "This resource is critical for helping health care professionals engage in informed decision-making and patient education regarding biosimilars, which are increasingly important in modern health care. " https://lnkd.in/e8KvU6Jq

The drug pipeline certainly is active. How can hospitals keep up? Specialty market trends expert Susan Trieu has the answers in her latest article, featured in Becker's Healthcare newsletter this week: https://bit.ly/4aJNkWc #pharmacy #specialtypharmacy #pharma #biosimilars #HSSPoutcomes #marketaccess

The European Federation of Pharmaceutical Industries and Associations (EFPIA) published the 2023 Patient W.A.I.T. data last month, and the results are consistent with previous years. Consistent in that depending on where rare disease patients live in Europe, their access to new therapeutics varies greatly despite a centralized approval in most of those countries. It also points to the importance of companies having early access programs in place to meet this unmet medical need. There remains much work to do.

This slide from this week's Festival of Biologics USA highlighted the dysfunction in our healthcare system. Despite having 8 biosimilar competitors, Humira still holds a whopping 97% of the market share. However, Kaiser Permanente physicians, pharmacists, and patients are setting a great example with over 90% adoption of the adalimumab biosimilar. This is great news for patients as biosimilar competition lowers the cost of biologics, making them more affordable. According to IQVIA, biosimilar use could save our nation a staggering $180 billion in healthcare costs by 2027. Let's hope the US can realize these savings while keeping more people healthy. #healthcare #biosimilar #affordablemedicine #healthcosts #KaiserPermanente

Biosimilars are emerging as a transformative force in healthcare, reshaping the way we approach and access medical treatments. They are reducing costs and improving access to vital treatments all over the world. Read more about how biosimilars are reshaping medicine in our latest blog here: https://lnkd.in/eivU2G7t #blog #medicine #biosimilars #pharma #generics

Curious how a patient-first approach can transform your clinical research? In our latest blog, Benjamin Piske and Cedric Marchand offer valuable insights on integrating patient journey-centric study designs into clinical trials from a CRO perspective. Read the full article to learn more 👉https://hubs.ly/Q02H3ltz0 #ClinicalTrials #PatientEngagement #CRO #ClinicalResearch #PatientExperience #adaptivetrialdesigns #DecentralizedTrials #datastrategy #LifeSciences #Pharma #biotech

Dr. Milind Antani, Lead- Pharma, Healthcare, Medical Device and Digital Healthcare practice, Nishith Desai Associates, shed light on the dynamic changes in diseases, illnesses, and patient profiles driven by various factors in this new age. To tackle these shifts, he emphasized the critical role of the pharmaceutical industry in pioneering new solutions to address and eliminate mutating diseases. #ValueOfInnovation #BharatKeLiye

Meet Georghia Michael, one of our Market Access Consultants.  With an academic background in cardiology research and over 10 years of experience writing for pharmaceutical companies, medical communication companies, and not-for-profit organizations, Georghia uses her expertise in content development to distil and communicate complex medical evidence and to create compelling strategic messaging. Georghia knows that pricing challenges are one of the biggest obstacles to market access at the moment. With this in mind, she is most excited to see how the current pricing challenges are being approached. There are so many unique, potentially curative treatments coming to market, and she knows there's a balance to be struck between properly compensating pharma companies for developing these technologies and maintaining a price that healthcare providers are likely to reimburse. Learn more about Georghia and our other experts at https://lnkd.in/eE8ck6hv #MarketAccessExpert

The future of Alzheimer's medication is looking increasingly hopeful, thanks to the dedicated efforts of various organizations, nonprofits and pharmaceutical companies working tirelessly to advance healthcare solutions. To help you stay informed, we're sharing a helpful guide to Alzheimer's disease medications: https://heyor.ca/fwAGBx

Texas Society of Hospital Pharmacists (TSHP) Round Rock, TX April 5-7 Located in the heart of Texas Hill Country, Round Rock is rich in history, abundant in local culture, and the host to this year’s Texas Society of Hospital Pharmacists.  Meitheal’s Pete Saxe is there and ready to answer your questions, so stop by our booth to learn more about how we are bringing stabilization to Generics, and expanding into Biologics and Biosimilars. By doing so, we continue to simplify access to life-changing medicine, for the common good. Think sustainability, think Meitheal. #HospitalPharmacy #Pharma #Generics #biosimilars